| Identification | Back Directory | [Name]
7-[2-[[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]amino]ethyl]-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione monohydrochloride | [CAS]
2572-61-4 | [Synonyms]
Nsc293888
Theodrenaline hydrochloride
7-[2-[[2-(3,4-Dihydrophenyl)-2-hydroxyethyl]amino]ethyl]-3,7-dihydro-1,3-dimethyl-H-purin-2,6-dionmonohydrochlorid
7-[2-[[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]amino]ethyl]-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione monohydrochloride | [EINECS(EC#)]
219-920-0 | [Molecular Formula]
C17H22ClN5O5 | [MOL File]
2572-61-4.mol | [Molecular Weight]
411.84 |
| Hazard Information | Back Directory | [Uses]
Theodrenaline hydrochloride is a cardiac stimulant, also acts as an anti-hypotensive agent together with Cafedrine. | [in vivo]
AkrinorTM produces significant potentiation of FSK effects, conceivable by PDE-inhibition, only at very high, clinically irrelevant concentrations of 420 mg/L[1]. | [References]
[1] Kloth B, et al. AkrinorTM, a Cafedrine/ Theodrenaline Mixture (20:1), Increases Force of Contraction of Human Atrial Myocardium But Does Not Constrict Internal Mammary Artery In Vitro. Front Pharmacol. 2017 May 23;8:272. DOI:10.3389/fphar.2017.00272 |
|
|